Literature DB >> 2492255

Effectiveness and cost of community care for schizophrenic patients.

H Häfner1, W an der Heiden.   

Abstract

Schizophrenic patients in Mannheim, West Germany, were studied to determine whether psychiatric treatment in the community reduces duration and frequency of rehospitalization, whether it has an impact on symptomatology and behavior, and whether it can be provided less expensively than hospital care. The findings showed a relationship between increased psychiatric outpatient treatment and lower levels of inpatient care as well as between psychiatric aftercare and reduced symptomatology and disease-related behavior. The cost of community care was found to be substantially lower than that of hospital care for less disabled patients, but it exceeded the cost of hospital care for the more severely disabled.

Entities:  

Mesh:

Year:  1989        PMID: 2492255     DOI: 10.1176/ps.40.1.59

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  6 in total

Review 1.  Cost-effectiveness studies in the treatment of schizophrenia: a review.

Authors:  D Goldberg
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1991-05       Impact factor: 4.328

Review 2.  Social psychiatry--an overview.

Authors:  S Fleck
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1990-01       Impact factor: 4.328

Review 3.  Mental health care costs: paucity of measurement.

Authors:  P McCrone; S Weich
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1996-03       Impact factor: 4.328

4.  Evaluation of care for the disabled mentally ill: theoretical issues.

Authors:  H Häfner; W an der Heiden
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Some aspects of the cost of schizophrenia in France.

Authors:  F Rouillon; M Toumi; G Y Dansette; J Benyaya; P Auquier
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

6.  [Health economic evaluation of community-based psychiatric interventions].

Authors:  R Kilian
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.